



**University of
Sunderland**

Holley, Mia, Razvi, Salman, Farooq, Mohammed Saif, Dew, Rosie, Maxwell, Ian and Wilkes, Scott (2024) Cardiovascular and bone health outcomes in older people with subclinical hypothyroidism treated with levothyroxine: a systematic review and meta-analysis. *Systematic reviews*, 13 (123). ISSN 2046-4053

Downloaded from: <http://sure.sunderland.ac.uk/id/eprint/17835/>

Usage guidelines

Please refer to the usage guidelines at <http://sure.sunderland.ac.uk/policies.html> or alternatively contact

sure@sunderland.ac.uk.

RESEARCH

Open Access



Cardiovascular and bone health outcomes in older people with subclinical hypothyroidism treated with levothyroxine: a systematic review and meta-analysis

Mia Holley^{1*} , Salman Razvi², Mohammed Saif Farooq¹, Rosie Dew¹, Ian Maxwell¹ and Scott Wilkes¹

Abstract

Background Thyroid dysfunction is common in older people, with females at higher risk. Evidence suggests that thyroid-stimulating hormone (TSH) levels naturally increase with age. However, as uniform serum TSH reference ranges are applied across the adult lifespan, subclinical hypothyroidism (SCH) diagnosis is more likely in older people, with some individuals also being commenced treatment with levothyroxine (LT4). It is unclear whether LT4 treatment in older people with SCH is associated with adverse cardiovascular or bone health outcomes.

Methods A systematic review and meta-analysis were performed to synthesise previous studies evaluating cardiovascular and bone health outcomes in older people with SCH, comparing LT4 treatment with no treatment. PubMed, Embase, Cochrane Library, MEDLINE, and Web of Science databases were searched from inception until March 13, 2023, and studies that evaluated cardiovascular and bone health events in people with SCH over 50 years old were selected.

Results Six articles that recruited 3853 participants were found, ranging from 185 to 1642 participants, with the proportion of females ranging from 45 to 80%. The paucity of data resulted in analysis for those aged over 65 years only. Additionally, a study with 12,212 participants aged 18 years and older was identified; however, only data relevant to patients aged 65 years and older were considered for inclusion in the systematic review. Of these 7 studies, 4 assessed cardiovascular outcomes, 1 assessed bone health outcomes, and 2 assessed both. A meta-analysis of cardiovascular outcomes revealed a pooled hazard ratio of 0.89 (95% CI 0.71–1.12), indicating no significant difference in cardiovascular risk between older individuals with SCH treated with LT4 compared to those without treatment. Due to overlapping sub-studies, meta-analysis for bone health outcomes was not possible.

Conclusions This systematic review and meta-analysis found no significant association between LT4 use and cardiovascular and bone health outcomes in SCH participants over 65 years.

Systematic review registration PROSPERO CRD42022308006

Keywords Subclinical hypothyroidism, Thyroid disease, Levothyroxine, Cardiovascular, Bone health

*Correspondence:

Mia Holley

mia.holley@sunderland.ac.uk

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Cardiovascular disease remains the leading cause of death worldwide, with ischaemic heart disease and stroke accounting for 8.9 million and 6.1 million deaths in 2019, respectively [1]. The United Kingdom (UK) population is increasing, and in 2018, it was predicted that by 2043, the number of people aged over 85 years will have nearly doubled to 3 million [2]. Each year, 160,000 deaths in the UK are attributed to cardiovascular events, accounting for approximately 23.9% of all deaths in the UK [3]. Several studies have found no association between subclinical hypothyroidism (SCH) and coronary heart disease, cerebrovascular, and peripheral arterial disease in the older population [4–8]. On the contrary, an association has been found between subclinical hyperthyroidism and cardiovascular risk [9, 10]. Moreover, several studies have explored the association between SCH and bone health outcomes in the ageing population, yielding inconsistent results [11–13].

Thyroid hormones are responsible for the metabolism in all tissues, including the heart, liver, brain, muscles, and bones, and thyroid hormone imbalance can lead to metabolic dysfunction [14]. The overall prevalence of hypothyroidism is approximately 5–10% in the general population in the UK, diagnosed when a person has elevated thyroid-stimulating hormone (TSH) levels [15]. SCH refers to TSH levels being higher than the accepted reference range, while free thyroxine levels remain within range [14].

Approximately 3.5% of the UK population is prescribed thyroid hormone replacement, and the number of prescriptions for levothyroxine (LT4) is increasing yearly [16, 17]. The goal of prescribing LT4 is to return the TSH level within the normal range and improve symptoms related to hypothyroidism. Since hypothyroidism is a chronic, irreversible condition, participants prescribed LT4 usually require long-term thyroid hormone treatment. The National Health and Nutrition Examination Survey (NHANES) study [18] and the Thyroid Epidemiology, Audit, and Research Study (TEARS) [19] found that serum TSH levels increase with age. The TEARS study indicated that the normal range for serum TSH could be 0.4–5.9 mU/L for participants aged 90 and over, rather than the 0.4–4.0 mU/L range currently used across all age groups in the UK [20]. The National Institute for Health and Care Excellence has recognised that TSH levels between 4.0 and 7.0 mU/L could be typical with ageing [21]. A review of cross-sectional studies estimated that nearly half the participants prescribed LT4 are either over or under-treated [22]. Both under- and over-treatment with thyroid hormones can be associated with adverse effects, particularly in older individuals, at higher risk of thyroid hormone toxicity [23].

This systematic review and meta-analysis aimed to combine the current literature on cardiovascular and bone health outcomes in SCH participants aged over 50 years to assess whether older individuals with SCH have worse cardiovascular and bone health outcomes when prescribed LT4. More specifically, this review compared the results of participants prescribed LT4 versus those untreated. This review was registered on PROSPERO, an international database of prospectively registered systematic reviews in health and social care (registration number CRD42022308006). No protocol was prepared for this review.

Methods

Search strategy

The Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines were employed in this review (Additional file 1) [24]. Two reviewers, MH and MSF, independently searched the Web of Science, Cochrane Library, MEDLINE, and EMBASE databases from inception until March 13, 2023. Any conflicts were resolved by a third reviewer, SW. Five terms were included in the search strategy based on disease, treatment, outcome event, age of participants, and study type (Additional file 2). Two reviewers, MH and MSF, removed the duplicates, and then the title and abstract of each article were screened against the inclusion criteria. The remaining articles had their full text filtered against the eligibility criteria, and their reference lists were checked for any additional qualifying studies.

Eligibility criteria

Studies with participants aged 50 years or older diagnosed with SCH were eligible. An intervention group of participants taking LT4 and a control group of participants taking a placebo or no medication were required. Only full-text articles published in English with the study type randomised control trial (RCT), cohort study, case-control study, cross-sectional study, or longitudinal study design were considered.

Articles that included participants diagnosed with thyroid cancer, pituitary disease, secondary hypothyroidism, overt hypothyroidism, tertiary hypothyroidism, or hyperthyroidism were excluded. Also, articles including participants receiving a different form of thyroid replacement therapy to LT4 were excluded from this review. Studies examining participants exclusively with a history of cardiovascular disease or studies on pregnant females were also excluded.

Outcome measures

Studies were required to evaluate the number of participants who experienced a cardiovascular event (ischemic

heart disease, peripheral vascular disease, cerebrovascular disease, coronary angioplasty, or cardiovascular death) or experienced a bone health outcome (osteoporosis or a fragility fracture) since LT4 treatment was commenced. These two outcomes were grouped separately for synthesis. The following covariates were also considered to enable subgroup analyses: age, sex, LT4 dose, and TSH levels.

Data extraction

Two independent reviewers, MH and MSF, screened the relevant articles against the eligibility criteria. A third reviewer (SW) resolved any conflicts. Data extraction of each study was completed, including the following details where possible:

- i. Authors, title, and publication year
- ii. Study period, study design, and number of participants
- iii. Population demographics, e.g. age and sex
- iv. LT4 dosage, frequency, and length of time prescribed
- v. The number of participants experiencing a cardiovascular or bone health outcome

Any missing data were assumed to have not been collected.

The quality of studies was assessed using the Cochrane risk of bias tool for RCTs [25, 26] and the Newcastle–Ottawa scale for non-randomised trials [27]. The quality of evidence was assessed using Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) guidelines [28, 29]. The assessment of both the quality of studies and the quality of evidence was independently carried out by two reviewers, MH and MSF.

Data analysis

Statistical analysis was conducted using R, implementing the ‘metafor’ package. Heterogeneity was assessed through the I^2 statistic such that if $I^2=0\%$, there was no heterogeneity; if $I^2<50\%$, there was moderate heterogeneity; if $I^2>50\%$, there was substantial heterogeneity [30]. Studies were pooled depending on their outcome measures—cardiovascular and bone health. The principal analysis was based on a random-effects model, pooling all suitable studies using hazard ratios (HR).

Sensitivity analysis

A sensitivity analysis was conducted to ensure the integrity of the data. We checked for any potential duplication of participants in the studies, ensuring that each participant was counted only once.

Results

Search results

There were 1530 articles identified upon the initial search (Fig. 1), with 462 duplicates. The remaining 1068 articles had their abstracts and titles screened, resulting in a further 1031 articles being excluded. The outstanding 37 articles were then fully assessed, including their reference lists [4, 7, 8, 12, 31–63]. No additional articles were found through searching reference lists. Seven articles remained in this review after reviewing the 37 articles against the specified criteria [12, 58–63]. The studies ranged from 185 to 12,212 participants. However, while one database study included 12,212 participants aged 18 years and older, it did not precisely outline the number of participants aged 65 years and over.

Study characteristics

Two reviewers, MH and MSF, independently selected and extracted outcome data from the selected studies and their study characteristics (Table 1). Notably, one study included individuals aged 18 years and over; however, incidence risk ratios for patients aged 65 years and older were published [58]. Two studies pooled the results of the Institute for Evidence-Based Medicine in Old Age 80-plus thyroid (IEMO80+) RCT trial (trial number NTR3851) and the Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism (TRUST) RCT trial (trial number NCT01660126) [59, 63]. The IEMO80+ trial included 105 participants with SCH 80 years and older; the TRUST trial included 737 participants with SCH 65 years and older. One study pooled the complete results of the two trials [59]; the other study only pooled the results of participants aged 80 years and over [63]. Two studies were nested sub-studies of the TRUST trial [12, 61]. One sub-study included 196 participants based at two of the study centres in Switzerland [12]; the other sub-study included 185 participants who underwent echocardiography [61]. Additionally, one study incorporated the results from all 737 participants in the TRUST trial [62]. No article was found publishing the data of the IEMO80+ trial individually.

Study outcomes

Six studies examined cardiovascular outcomes (Table 2) [58–63]. Three studies assessed total cardiovascular events, including both fatal and non-fatal [59, 62, 63]. All three studies found a HR of less than 1, with the lowest HR found by the pooled study on participants aged over 80 years (HR 0.61; 95% confidence interval (CI) 0.24–1.50) [63]. However, all three studies had 95% CIs suggesting small sample sizes and no significant difference in cardiovascular outcomes in older SCH participants




Fig. 1 PRISMA flow diagram

regardless of LT4 treatment. One sub-study looked at total cardiovascular events but did not calculate an adjusted HR due to the small sample size [61]. The raw outputs of the study showed no association between cardiovascular outcomes and LT4 (OR 1.09; 95% CI 0.35–3.37). The two observational database studies looked at cardiovascular mortality [58, 60]. One database study found no association between cardiovascular mortality and LT4 use (HR 1.04; 95% CI 0.56–1.93) [60]. The other database study also found no significant differences in cardiovascular outcomes regardless of LT4 use (incidence rate ratio (IRR) 1.08; 95% CI 0.88–1.34) [58]. The two observational studies had the longest follow-up time, following patients for over 3 years; the other studies had a maximum follow-up time of 3 years.

Three studies examined bone health outcomes, totaling 1184 participants (Table 3) [12, 62, 63]. Among these, 2 studies looked only at fracture outcomes, and 1 looked at both fracture and osteoporosis outcomes. The study reporting on both outcomes found no association between fractures and LT4 use (HR 1.06; 95% CI 0.41–2.76) or a new diagnosis of osteoporosis (HR 0.75; 95% CI

0.17–3.37) [62]. No study found a significant difference in bone health outcomes of SCH participants aged over 65 years regardless of LT4 use.

Quality assessment

Each bias type was categorised as low, moderate, or high in line with the Cochrane Risk of Bias Tool for all five RCT studies (Additional file 3). Since the five studies incorporated two RCTs, the risk of bias was similar for all studies. Three studies were classified as low risk [12, 61, 62] and two as moderate risk [59, 63]. Non-randomised trials were given seven or eight stars on the Newcastle–Ottawa scale (Additional file 4). One study experienced quality reduction due to the non-exclusion of participants with cardiovascular problems at baseline [58]. GRADE quality of evidence assessment found a high quality of evidence for six studies (Additional file 5). The remaining study had a moderate overall quality of evidence due to a moderate risk of bias and serious imprecision [63]. Given the paucity of articles ($n < 10$), publication bias was not investigated in this systematic review [25, 64].

Table 1 Study characteristics, including median levothyroxine (LT4) dose ($\mu\text{g}/\text{day}$) and mean thyroid-stimulating hormone (TSH) levels (mIU/L)

First author, year	Country	Study design	N (total)	N (treatment group)	N (control group)	Age of participants	Women (%)	Median LT4 dose ($\mu\text{g}/\text{day}$)	Mean TSH (mIU/L) at baseline (LT4, no LT4)
Andersen, 2015 [58]	Denmark	Retrospective database analysis	12,212 ^a	2483 ^a	9729 ^a	≥ 65 years	79.8 ^a	80	6.9 ^b
Gencer, 2020 [61]	Switzerland	Randomised controlled trial	185	96	89	≥ 65 years	47.0	50	6.26, 6.47
Gonzalez Rodriguez, 2020 [12]	Switzerland	Randomised controlled trial	196	100	96	≥ 65 years	45.4	50	6.3, 6.5
Mooijaart, 2019 [63]	Netherlands, Switzerland, Ireland, and the UK	Pooled results of two randomised controlled trials	251 (N1 = 146, N2 = 105)	112 (N1 = 60, N2 = 52)	139 (N1 = 86, N2 = 53)	≥ 80 years	47.0	50	6.4, 6.3
Razvi, 2012 [60]	UK	Retrospective database analysis	1642	819	823	> 70 years	80.1	75	6.77, 6.32
Stott, 2017 [62]	Netherlands, Switzerland, Ireland, and the UK	Randomised controlled trial	737	368	369	≥ 65 years	53.7	50	6.41, 6.38
Zijlstra, 2021 [59]	Netherlands, Switzerland, Ireland, and the UK	Pooled results of two randomised controlled trials	842 (N1 = 737, N2 = 105)	420 (N1 = 368, N2 = 52)	422 (N1 = 369, N2 = 53)	≥ 65 years	53.2	50	6.5, 6.4

^a Based on the total population (18 years and over)

^b Median levels based on the total population (18 years and over)

Meta-analysis

A meta-analysis was conducted for the primary outcome. The pooled HRs of the four studies are presented, of which one study calculated two HRs for two different outcome events. The pooled HR found no association between LT4 use and cardiovascular outcomes in 3668 SCH participants over 65 (pooled HR 0.86; 95% CI 0.73–1.02) (Fig. 2). No heterogeneity existed between the six articles investigating cardiovascular outcomes ($I^2 = 0\%$).

Due to the overlap between studies, a second analysis was carried out. The second analysis included data from one database study and one pooled study, which reported on the outcomes of all 737 participants in the TRUST trial and 105 participants in the IEMO80+ trial to exclude overlapping participants [60, 62]. This analysis of 2484 participants found no association between LT4 use and cardiovascular outcomes (pooled HR 0.89; 95% CI 0.71–1.12) (Fig. 3). No heterogeneity existed between the two articles ($I^2 = 0\%$).

A meta-analysis for the secondary outcome was not conducted as the three articles that investigated bone health outcomes all used data from the TRUST study,

including the complete TRUST study and two sub-studies derived from the TRUST study.

Discussion

Main findings

The cardiovascular and bone health-related outcomes for participants over 65 years and prescribed LT4 remain inconclusive. There was a paucity of studies looking at the bone health and cardiovascular outcomes of LT4 in older SCH subjects. In particular, no studies were found on participants between 50 and 65 years old. The meta-analysis showed no association between adverse cardiovascular outcomes and LT4 use or not, in SCH participants over 65 years, and identified a gap in the literature for LT4 outcomes in participants with SCH between the ages of 50 and 65 years.

Strengths and limitations

This is the largest systematic review and meta-analysis to date. The main limitation of this systematic review was the lack of suitable studies with large sample sizes and adequate power, particularly looking at bone health

Table 3 Comparison of bone health outcomes between patients prescribed levothyroxine (LT4) and those not prescribed LT4, including raw numbers, hazard ratios (HR), estimated risk difference, and 95% confidence intervals (CI)

First author, year	Model adjustments	Total bone health results		Fracture results		Osteoporosis results	
		LT4	No LT4	LT4	No LT4	LT4	No LT4
Gonzalez Rodriguez, 2020 [12]	No adjustments made	–	–	–	3	–	–
Mooijaart, 2019 [63]	No adjustments made	–	–	4	5	–	–
				Estimated risk difference (95% CI) 0.00 (–0.04–0.03)		–	–
Stott, 2017 [62]	Country, sex, and starting dose of LT4	12	12	9	8	3	4
				HR (95% CI) 1.06 (0.41–2.76)		–	–




Fig. 2 Forest plot of all studies for the association of levothyroxine (LT4) with cardiovascular effects in subclinical hypothyroid (SCH) participants, presented by hazard ratios (HR) and 95% confidence intervals (CI)




Fig. 3 Forest plot of mutually exclusive studies for the association of levothyroxine (LT4) with cardiovascular effects in subclinical hypothyroid (SCH) participants, presented by hazard ratios (HR) and 95% confidence intervals (CI)

outcomes. This review could not find any articles about participants aged 50 to 65 years, and it identified just one article regarding osteoporosis outcomes. Only two studies had a follow-up period over 3 years, limiting the assessment of the long-term effects of LT4. Most studies included in the review had few participants or poor recruitment uptake, as demonstrated in the TRUST

RCT [62]. Furthermore, this systematic review was constrained by the small number of events in all the studies considered, except Razvi et al. [60] and Andersen et al. [58] as well as insufficient raw data on the IEMO80+ trial. The results of the IEMO80+ trial were shared in a publication that included combined findings from the TRUST study, both with participants aged 65 years and over and

with participants aged 80 years and over. This limited the meta-analysis as no adjusted risk estimate could be calculated individually for the IEMO80+ study. Nonetheless, the findings of all included studies are similar regardless of individual and pooled results.

Comparison with literature

The broader literature concludes that patients prescribed LT4 who have TSH levels above 10 mIU/L and are middle-aged or young adults have better cardiovascular outcomes [65]. Clinical practice guidelines for LT4 prescribing remain unchanged, indicating LT4 for adults when they have two TSH readings above 10 mIU/L at least 3 months apart [65]. The TRUST study identified challenges in conducting an RCT to provide guidance for LT4 prescribing for this group of patients, and a large epidemiological database study may provide further evidence.

Implications for clinical practice

This study represents the largest systematic review and meta-analysis to date and demonstrates no difference in cardiovascular health for older people with SCH whether LT4 treatment was initiated or not. The available data identified in this systematic review and meta-analysis lacks the power to give any new recommendations on prescribing LT4 for participants over 65 years with SCH. Prescribing for elderly patients with SCH will likely remain in equipoise with patient symptoms driving clinical practice.

Abbreviations

CI	Confidence interval
GRADE	Grading of Recommendations, Assessment, Development, and Evaluations
HR	Hazard ratio
IEMO80+	Institute for Evidence-Based Medicine in Old Age 80-plus thyroid
IRR	Incidence rate ratio
LT4	Levothyroxine
NHANES	National Health and Nutrition Examination Survey
OR	Odds ratio
PRISMA	Preferred Reporting Items for Systematic Review and Meta-Analysis
RCT	Randomised controlled trial
SCH	Subclinical hypothyroidism
TEARS	Thyroid Epidemiology, Audit, and Research Study
TRUST	Thyroid Hormone Replacement for Untreated Older Adults with Subclinical Hypothyroidism Trial
TSH	Thyroid-stimulating hormone
UK	United Kingdom

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13643-024-02548-7>.

Supplementary Material 1: (1) PRISMA checklist. (2) Search strategy. (3) Cochrane Risk of Bias Tool for all five RCT studies. (4) Newcastle-Ottawa Scale. (5) GRADE quality of evidence assessment.

Acknowledgements

Not applicable.

Authors' contributions

MH handled the protocol development, review execution, and manuscript drafting. MSF, the second reviewer, independently screened the studies, validated the data, and aided in the data analysis. SW, SR, RD, and IM contributed to the methods and provided feedback on the manuscript. All authors read and approved the final manuscript.

Funding

This study/project is funded by the National Institute for Health and Care Research (NIHR) Applied Research Collaboration North East and North Cumbria (NIHR200173). The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Availability of data and materials

This systematic review relies exclusively on the information from previously published studies, with no analysis of raw data conducted in the current study.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹School of Medicine, Faculty of Health Sciences and Wellbeing, University of Sunderland, Sunderland, UK. ²Translational and Clinical Research Institute, Newcastle University, Newcastle-Upon-Tyne, UK.

Received: 26 October 2023 Accepted: 29 April 2024

Published online: 08 May 2024

References

1. The World Health Organization. The top 10 causes of death. Available from: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>. Cited 2021 Nov 26.
2. National population projections - Office for National Statistics. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/bulletins/nationalpopulationprojections/2018based#changes-since-the-2016-based-projections>. Cited 2021 Nov 26.
3. British Heart Foundation. Heart Statistics. Available from: <https://www.bhf.org.uk/what-we-do/our-research/heart-statistics>. Cited 2021 Nov 29.
4. Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris TB, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. *Arch Intern Med*. 2005;165(21):2460–6.
5. Hyland KA, Arnold AM, Lee JS, Cappola AR. Persistent subclinical hypothyroidism and cardiovascular risk in the elderly: the cardiovascular health study. *J Clin Endocrinol Metab*. 2013;98(2):533–40.
6. de Jongh RT, Lips P, van Schoor NM, Rijs KJ, Deeg DJH, Comijs HC, et al. Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. *Eur J Endocrinol*. 2011;165(4):545–54.
7. Boekholdt SM, Titan SM, Wiersinga WM, Chatterjee K, Basart DCG, Luben R, et al. Initial thyroid status and cardiovascular risk factors: the EPIC-Norfolk prospective population study. *Clin Endocrinol (Oxf)*. 2010;72(3):404–10.
8. Waring AC, Harrison S, Samuels MH, Ensrud KE, LeBlanc ES, Hoffman AR, et al. Thyroid function and mortality in older men: a prospective study. *J Clin Endocrinol Metab*. 2012;97(3):862–70.

9. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, et al. Thyroid status, cardiovascular risk, and mortality in older adults. *JAMA*. 2006;295(9):1033–41.
10. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FDR, Wilson S, et al. Association between serum free thyroxine concentration and atrial fibrillation. *Arch Intern Med*. 2007;167(9):928–34.
11. Abrahamsen B, Jørgensen HL, Laulund AS, Nybo M, Bauer DC, Brix TH, et al. The excess risk of major osteoporotic fractures in hypothyroidism is driven by cumulative hyperthyroid as opposed to hypothyroid time: an observational register-based time-resolved cohort analysis. *J Bone Miner Res*. 2015;30(5):898–905.
12. Gonzalez Rodriguez E, Stuber M, Del Giovane C, Feller M, Collet TH, Löwe AL, et al. Skeletal effects of levothyroxine for subclinical hypothyroidism in older adults: a TRUST randomized trial nested study. *J Clin Endocrinol Metab*. 2020;105(11):dgz058.
13. Meier C, Beat M, Guglielmetti M, Christ-Crain M, Staub J, Kraenzlin M. Restoration of euthyroidism accelerates bone turnover in patients with subclinical hypothyroidism: a randomized controlled trial. *Osteoporos Int*. 2004;15(3):209–16.
14. Cooper DS, Biondi B. Subclinical thyroid disease. *Lancet*. 2012;379(9821):1142–54.
15. Okosieme O, Gilbert J, Abraham P, Boelaert K, Dayan C, Gurnell M, et al. Management of primary hypothyroidism: statement by the British Thyroid Association Executive Committee. *Clin Endocrinol (Oxf)*. 2016;84(6):799–808.
16. Mitchell AL, Hickey B, Hickey JL, Pearce SH. Trends in thyroid hormone prescribing and consumption in the UK. *BMC Public Health*. 2009;9(1):132.
17. Razvi S, Korevaar TIM, Taylor P. Trends, determinants, and associations of treated hypothyroidism in the United Kingdom, 2005–2014. *Thyroid*. 2019;29(2):174–82.
18. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab*. 2002;87(2):489–99.
19. Vadiveloo T, Donnan PT, Murphy MJ, Leese GP. Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the Thyroid Epidemiology, Audit, and Research Study (TEARS). *J Clin Endocrinol Metab*. 2013;98(3):1147–53.
20. Overview | Thyroid disease: assessment and management | Guidance | NICE. NICE; 2019. Available from: <https://www.nice.org.uk/guidance/ng145>. Cited 2023 Oct 5.
21. Assessment | Diagnosis | Hypothyroidism | CKS | NICE. Available from: <https://cks.nice.org.uk/topics/hypothyroidism/diagnosis/assessment/>. Cited 2023 Oct 5.
22. Eligar V, Taylor P, Okosieme O, Leese G, Dayan C. Thyroxine replacement: a clinical endocrinologist's viewpoint. *Ann Clin Biochem*. 2016;53(4):421–33.
23. Thyroid Disease in Aging - PMC. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9462896/#>. Cited 2023 Sep 25.
24. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;29(372):n71.
25. Sterne JAC, Egger M, Moher D, Boutron I (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors), *Cochrane Handbook for Systematic Reviews of Interventions* version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.
26. Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;18(343):d5928.
27. Ottawa Hospital Research Institute. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Cited 2023 Mar 23.
28. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. *BMJ*. 2004;328(7454):1490.
29. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. *J Clin Epidemiol*. 2011;64(4):401–6.
30. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327(7414):557–60.
31. World Health Organization Protocol EUCTR2012–004160–22-NL. IEMO 80-plus thyroid trial. 2013. Available from: <https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2012-004160-22-NL>.
32. Nygaard Andersen M, Schjerning-Olsen, Clausager Madsen J, Faber J, Torp-Pedersen C, Gislason G, et al. Major adverse cardiac events (MACE) and all-cause mortality in levothyroxine substituted individuals with subclinical hypothyroidism: a large cohort study. *Eur Heart J*. 2014;35:903.
33. Razvi S, Ingøe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. *J Clin Endocrinol Metab*. 2007;92(5):1715–23.
34. Razvi S, Weaver JU, Vanderpump MP, Pearce SHS. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. *J Clin Endocrinol Metab*. 2010;95(4):1734–40.
35. Alotaibe HF, Alolaiwi LA, Almutairi A, Alsubaie N, Badri M, Balaha MF, et al. Association between levothyroxine replacement therapy and osteoporosis in Riyadh, Saudi Arabia: a matched case-control study. *Pharmazie*. 2022;77(10):295–8.
36. Huang HK, Wang JH, Kao SL. Association of hypothyroidism with all-cause mortality: a cohort study in an older adult population. *J Clin Endocrinol Metab*. 2018;103(9):3310–8.
37. Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. *Eur J Endocrinol*. 2019;180(6):407–16.
38. Vestergaard P, Rejnmark L, Mosekilde L. Influence of hyper- and hypothyroidism, and the effects of treatment with antithyroid drugs and levothyroxine on fracture risk. *Calcif Tissue Int*. 2005;77(3):139–44.
39. Vinoli A, Hickstein L, Walker J, Donner-Banzhoff N, Baum E, Becker A. Influence of thyroid hormone therapy on the fracture rate - a claims data cohort study. *Bone*. 2016;86:86–90.
40. Lillevang-Johansen M, Abrahamsen B, Jørgensen HL, Brix TH, Hegedüs L. Over- and under-treatment of hypothyroidism is associated with excess mortality: a register-based cohort study. *Thyroid*. 2018;28(5):566–74.
41. Abbey EJ, McGready J, Ferrucci L, Simonsick EM, Mammen JSR. Thyroid hormone supplementation and all-cause mortality in community-dwelling older adults: results from the Baltimore Longitudinal Study of Aging. *J Am Geriatr Soc*. 2021;69(5):1283–90.
42. Thayakaran R, Adderley NJ, Sainsbury C, Torlinska B, Boelaert K, Šumilo D, et al. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. *BMJ*. 2019;3(366):14892.
43. Waring AC, Harrison S, Fink HA, Samuels MH, Cawthon PM, Zmuda JM, et al. A prospective study of thyroid function, bone loss, and fractures in older men: the MrOS study. *J Bone Miner Res*. 2013;28(3):472–9.
44. Inoue K, Ritz B, Brent GA, Ebrahimi R, Rhee CM, Leung AM. Association of subclinical hypothyroidism and cardiovascular disease with mortality. *JAMA Netw Open*. 2020;3(2):e1920745.
45. Pearce SHS, Razvi S, Yadegarfar ME, Martin-Ruiz C, Kingston A, Collerton J, et al. Serum thyroid function, mortality and disability in advanced old age: the Newcastle 85+ Study. *J Clin Endocrinol Metab*. 2016;101(11):4385–94.
46. Giri A, Edwards TL, LeGrys VA, Lorenz CE, Funk MJ, Schechtman R, et al. Subclinical hypothyroidism and risk for incident ischemic stroke among postmenopausal women. *Thyroid*. 2014;24(8):1210–7.
47. Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. *Ann Intern Med*. 2000;132(4):270–8.
48. Tseng FY, Lin WY, Lin CC, Lee LT, Li TC, Sung PK, et al. Subclinical hypothyroidism is associated with increased risk for all-cause and cardiovascular mortality in adults. *J Am Coll Cardiol*. 2012;60(8):730–7.
49. Silva N, Santos O, Morais F, Gottlieb I, Hadlich M, Rothstein T, et al. Subclinical hypothyroidism represents an additional risk factor for coronary artery calcification, especially in subjects with intermediate and high cardiovascular risk scores. *Eur J Endocrinol*. 2014;171(3):327–34.
50. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. *Arch Intern Med*. 2005;165(21):2467–72.

51. Chaker L, van den Berg ME, Niemeijer MN, Franco OH, Dehghan A, Hofman A, et al. Thyroid function and sudden cardiac death: a prospective population-based cohort study. *Circulation*. 2016;134(10):713–22.
52. Bano A, Chaker L, Mattace-Raso FUS, van der Lugt A, Ikram MA, Franco OH, et al. Thyroid function and the risk of atherosclerotic cardiovascular morbidity and mortality: the Rotterdam Study. *Circ Res*. 2017;121(12):1392–400.
53. Martin SS, Daya N, Lutsey PL, Matsushita K, Fretz A, McEvoy JW, et al. Thyroid function, cardiovascular risk factors, and incident atherosclerotic cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC) Study. *J Clin Endocrinol Metab*. 2017;102(9):3306–15.
54. Ceresini G, Ceda GP, Lauretani F, Maggio M, Usberti E, Marina M, et al. Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: the aging in the Chianti Area Study. *J Am Geriatr Soc*. 2013;61(6):868–74.
55. Maraka S, Owen R, Ospina NS, Knox M, Dodds T, Spencer H, Dishongh K, Albashaireh A, Shah A, Syed S, Naqvi S, Motahari H, Thumma S, Ambrogini E, Brito J. Discontinuation of low-dose levothyroxine therapy for patients with subclinical hypothyroidism is feasible and safe: interim analysis of a pilot, randomized, double-blind, placebo-controlled trial. *Thyroid*. 2022;32:A49.
56. Grossman A, Feldhamer I, Meyerovitch J. Treatment with levothyroxin in subclinical hypothyroidism is associated with increased mortality in the elderly. *Eur J Intern Med*. 2018;50:65–8.
57. Wouters HJCM, Slagter SN, Muller Kobold AC, van der Klauw MM, Wolffenbuttel BHR. Epidemiology of thyroid disorders in the Lifelines Cohort Study (the Netherlands). *PLoS ONE*. 2020;15(11):e0242795.
58. Andersen MN, Olsen AMS, Madsen JC, Faber J, Torp-Pedersen C, Gislason GH, et al. Levothyroxine substitution in patients with subclinical hypothyroidism and the risk of myocardial infarction and mortality. *PLoS ONE*. 2015;10(6):e0129793.
59. Zijlstra L, Jukema J, Westendorp R, Du Puy R, Poortvliet R, Kearney P, et al. Levothyroxine treatment and cardiovascular outcomes in older people with subclinical hypothyroidism: pooled individual results of two randomised controlled trials. *Front Endocrinol*. 2021;12:674841.
60. Razvi S, Weaver JU, Butler TJ, Pearce SHS. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. *Arch Intern Med*. 2012;172(10):811–7.
61. Gencer B, Moutzouri E, Blum MR, Feller M, Collet TH, Delgiovane C, et al. The impact of levothyroxine on cardiac function in older adults with mild subclinical hypothyroidism: a randomized clinical trial. *Am J Med*. 2020;133(7):848–856.e5.
62. Stott D, Rodondi N, Kearney P, Ford I, Westendorp R, Mooijaart S, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. *N Engl J Med*. 2017;376(26):2534–44.
63. Mooijaart SP, Du Puy RS, Stott DJ, Kearney PM, Rodondi N, Westendorp RGJ, et al. Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism. *JAMA*. 2019;322(20):1977–86.
64. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629–34.
65. Recommendations | Thyroid disease: assessment and management | Guidance | NICE. NICE; Available from: <https://www.nice.org.uk/guidance/ng145/chapter/Recommendations#terms-used-in-this-guideline>. Cited 2022 Feb 8.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.